Singh Harpreet, Jalodia Sunil, Gupta M S, Talapatra Paulomi, Gupta Vikas, Singh Ishwar
Department of Medicine, Pandit B.D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.
Ann Indian Acad Neurol. 2012 Jul;15(3):177-80. doi: 10.4103/0972-2327.99705.
To study the effect of intravenous magnesium sulfate infusion on clinical outcome of patients of acute stroke.
Sixty consecutive cases of acute ischemic stroke hospitalised within 24 h of an episode of stroke were taken as subjects. All subjects underwent a computed tomography head, and those found to have evidence of bleed/space-occupying lesions were excluded from the study. The subjects taken up for the study were divided into two groups of 30 subjects each. Both the groups received the standard protocol management for acute ischemic stroke. Subjects of Group 1 additionally received intravenous magnesium sulfate as initial 4 g bolus dose over 15 min followed by 16 g as slow infusion over the next 24 h. In all the subjects of the two study groups, serum magnesium levels were estimated at the time of admission (Day 0), Day 1 and Day 2 of hospitalization using an atomic absorption spectrometer.
Scandinavian stroke scores were calculated on Day 3, day of discharge and Day 28. Paired t-test was employed for comparison of stroke scores on Day 3, day of discharge and Day 28 within the same group and the unpaired t-test was used for the intergroup comparison, i.e. comparison of stroke scores of control group with corresponding stroke scores of magnesium group.
Comparison of stroke scores on Day 3 and day of discharge, on the day of discharge and Day 28 and on Day 3 and Day 28 in the magnesium group produced a t-value of 5.000 and P <0.001, which was highly significant. However, the comparison of the mean stroke scores between the magnesium and the control groups on Day 3, day of discharge and Day 28 yielded a P-value of >0.05, which was not significant.
The study failed to document a statistical significant stroke recovery in spite of achieving a significant rise in serum magnesium level, more than that necessary for neuroprotection, with an intravenous magnesium sulfate regime.
研究静脉输注硫酸镁对急性中风患者临床结局的影响。
选取60例在中风发作后24小时内入院的急性缺血性中风连续病例作为研究对象。所有研究对象均进行了头颅计算机断层扫描,发现有出血/占位性病变迹象的患者被排除在研究之外。参与研究的对象被分为两组,每组30名。两组均接受急性缺血性中风的标准方案治疗。第1组患者额外接受静脉输注硫酸镁,初始剂量为4克,在15分钟内推注,随后在接下来的24小时内缓慢输注16克。在两个研究组的所有研究对象中,入院时(第0天)、住院第1天和第2天使用原子吸收光谱仪测定血清镁水平。
在第3天、出院日和第28天计算斯堪的纳维亚中风评分。采用配对t检验比较同一组内第3天、出院日和第28天的中风评分,采用非配对t检验进行组间比较,即比较对照组与硫酸镁组相应的中风评分。
硫酸镁组在第3天与出院日、出院日与第28天以及第3天与第28天的中风评分比较,t值为5.000,P<0.001,具有高度显著性。然而,硫酸镁组与对照组在第3天、出院日和第28天的平均中风评分比较,P值>0.05,无显著性差异。
尽管通过静脉输注硫酸镁方案使血清镁水平显著升高,超过了神经保护所需水平,但该研究未能证明中风恢复有统计学意义。